Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease - 03/03/25
, Azeem Latib, MD b, Darren Mylotte, MD, PhD c, Ziad A. Ali, MD, DPhil d, Azfar Zaman, MD e, Sandeep Brar, MD f, Maria Parke, MS f, Bruno Scheller, MD gHighlights |
• | In-stent restenosis (ISR) and small vessel disease (SVD) remain difficult to treat. |
• | Drug-coated balloons (DCB) are an alternative treatment option for ISR and SVD. |
• | Prevail global is a clinical trial that will assess the prevail DCB in ISR and SVD. |
Résumé |
Background and Rationale |
In-stent restenosis (ISR) remains the leading cause of treatment failure following percutaneous coronary intervention (PCI) with contemporary drug-eluting stents. Especially in small caliber coronary arteries, restenosis is common following PCI and represents a treatment challenge. Drug-coated balloons (DCB) are an attractive alternative to stents for treatment of both ISR and small vessel disease. The safety and efficacy of the Prevail DCB will be assessed for (1) the treatment of ISR and (2) de novo lesions in small vessels.
Trial Design |
Prevail Global is a prospective, international, dual cohort clinical study enrolling (1) patients undergoing PCI for ISR in a randomized controlled trial (1:1) design comparing the Prevail DCB versus an FDA-approved DCB (AgentTM, Boston Scientific Corporation, Natick MA), and (2) patients with de novo small vessel disease undergoing PCI with the Prevail DCB as part of a single-arm study compared with a historical control. The primary endpoint is target lesion failure, defined as a composite of cardiac death, target vessel myocardial infarction, or clinically-driven target lesion revascularization at 12 months post procedure. Patient follow-up is planned for 1 month, 6 months, and yearly through 5 years. Enrollment is expected to start in early 2025.
Conclusions |
The Prevail Global study will directly assess the safety and efficacy of the Prevail DCB for the treatment of ISR and de novo small vessel lesions.
Trial Registration |
Prevail Global, NCT06535854, is registered at NCT06535854.
Le texte complet de cet article est disponible en PDF.Plan
Vol 283
P. 26-36 - mai 2025 Retour au numéro
Article précédent
- Higher levels of glucose within the normal range and cardiovascular risk: A landscape beyond diabetes and prediabetes
- Moein Ebrahimi, Gregg C. Fonarow
- Randomized comparison of the combined Sirolimus eluting and endothelial progenitor cell combo Stent vs. biolimus eluting absorbable polymer coated biomatrix alpha stent in patients undergoing percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for randomized trials with clinical outcome (SORT OUT) XI trial
- Ashkan Eftekhari, Evald Høj Christiansen, Jens Flensted Lassen, Bent Raungaard, Lars Jakobsen, Lisette Okkels Jensen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?